GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma)

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering

BIO US 2021 – Digital

GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

KOL Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment

GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19

BioEurope Spring – virtual